Bio Net Receivables from 2010 to 2026

TECH Stock  USD 64.68  0.57  0.87%   
Bio Techne's Net Receivables is increasing with slightly volatile movements from year to year. Net Receivables is estimated to finish at about 249.8 M this year. For the period between 2010 and 2026, Bio Techne, Net Receivables quarterly trend regression had mean deviation of  65,180,571 and range of 247.3 M. View All Fundamentals
 
Net Receivables  
First Reported
1989-09-30
Previous Quarter
206.9 M
Current Value
183.9 M
Quarterly Volatility
65.5 M
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Bio Techne financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Techne's main balance sheet or income statement drivers, such as Depreciation And Amortization of 132.7 M, Total Revenue of 1.5 B or Gross Profit of 954.3 M, as well as many indicators such as Price To Sales Ratio of 6.86, Dividend Yield of 0.0106 or PTB Ratio of 6.72. Bio financial statements analysis is a perfect complement when working with Bio Techne Valuation or Volatility modules.
  
Build AI portfolio with Bio Stock
Check out the analysis of Bio Techne Correlation against competitors.
The Net Receivables trend for Bio Techne Corp offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Bio Techne is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Bio Techne's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Bio Techne Corp over the last few years. It is Bio Techne's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bio Techne's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Bio Net Receivables Regression Statistics

Arithmetic Mean134,726,539
Geometric Mean96,963,445
Coefficient Of Variation58.66
Mean Deviation65,180,571
Median122,534,000
Standard Deviation79,033,872
Sample Variance6246.4T
Range247.3M
R-Value0.98
Mean Square Error242.6T
R-Squared0.96
Slope15,363,497
Total Sum of Squares99941.6T

Bio Net Receivables History

2026249.8 M
2025237.9 M
2024206.9 M
2023241.4 M
2022218.5 M
2021194.5 M
2020145.4 M

About Bio Techne Financial Statements

Investors use fundamental indicators, such as Bio Techne's Net Receivables, to determine how well the company is positioned to perform in the future. Although Bio Techne's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Receivables237.9 M249.8 M

Currently Active Assets on Macroaxis

When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:
Check out the analysis of Bio Techne Correlation against competitors.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is there potential for Life Sciences Tools & Services market expansion? Will Bio introduce new products? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.143
Dividend Share
0.32
Earnings Share
0.49
Revenue Per Share
7.762
Quarterly Revenue Growth
(0.01)
Understanding Bio Techne Corp requires distinguishing between market price and book value, where the latter reflects Bio's accounting equity. The concept of intrinsic value—what Bio Techne's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Bio Techne's price substantially above or below its fundamental value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Bio Techne's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.